ERBB2 and neoplasm: We could also show that EGFR and HER2 gene amplifications were most common among the intestinal-type tumours with EBV negativity, MSS and TP53 aberration, of which 17.3% (17/98) were EGFR and 15.3% (15/98) HER2 amplified.